Key points from article :
Turn.bio is working to induce pluripotence in cells in vivo.
Initial studies in mice, surprisingly, did not result in cancer increase.
Benefits to health and tissue function looked like the results of stem cell therapies.
Likely achieved via signaling produced by the newly induced pluripotent stem cells.
Tests carried out on fibroblasts and endothelial cells from aged human subjects.
Transient reprogramming triggers a more youthful gene expression profile, while retaining cell identity.
Temporary nature of treatment may also reduce long term risks.
Turn Biotechnologies' CEO, Gary Hudson, is also a founding partner of Oisin Biotechnologies.
